Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Minetta C Liu
Academic and Community Cancer Research United
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- University of Illinois
Chicago, Illinois, United States
- Illinois Cancercare-Peoria
Peoria, Illinois, United States
- Carle Cancer Center Nci Community Oncology Research Program
Urbana, Illinois, United States
- Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, United States
- Iowa-Wide Oncology Research Coalition Ncorp
Des Moines, Iowa, United States
- Siouxland Regional Cancer Center
Sioux City, Iowa, United States
- Cancer Center of Kansas - Wichita
Wichita, Kansas, United States
- Ochsner Nci Community Oncology Research Program
New Orleans, Louisiana, United States
- Lafayette Family Cancer Center-Emmc
Brewer, Maine, United States
- Cancer Research Consortium of West Michigan Ncorp
Grand Rapids, Michigan, United States
- Essentia Health Nci Community Oncology Research Program
Duluth, Minnesota, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, United States
- University of Missouri - Ellis Fischel
Columbia, Missouri, United States
- Heartland Regional Medical Center
Saint Joseph, Missouri, United States
- Heartland Cancer Research Ccop
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Cancer Alliance of Nebraska
Omaha, Nebraska, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- New Hampshire Oncology Hematology Pa-Hooksett
Hooksett, New Hampshire, United States
- Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
- Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, United States
- Mission Hospital-Saint Joseph Campus
Asheville, North Carolina, United States
- Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, United States
- Firsthealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina, United States
- Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, United States
- Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- Women and Infants Hospital
Providence, Rhode Island, United States
- Rapid City Regional Hospital
Rapid City, South Dakota, United States
- Edwards Comprehensive Cancer Center
Huntington, West Virginia, United States
- Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Jan 2014
- Primary completion
- 11 Feb 2021
- Completion
- 31 Oct 2024
- Last update posted
- 20 Aug 2024
- Registered enrollment
- 201
- Registry id
- NCT02037529
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.